Clinical Trial Update: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing trilaciclib versus placebo in patients with extensive-stage small cell lung cancer receiving topotecan is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 4 | Status: RECRUITING